Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · October 25, 2023

Outcomes of Using Cefepime vs Piperacillin–Tazobactam in Adults Hospitalized With Acute Infection

JAMA: The Journal of the American Medical Association


Additional Info

JAMA: The Journal of the American Medical Association
Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial
JAMA 2023 Oct 14;[EPub Ahead of Print], ET Qian, JD Casey, A Wright, L Wang, MS Shotwell, JK Siemann, ML Dear, JL Stollings, BD Lloyd, TK Marvi, KP Seitz, GE Nelson, PW Wright, ED Siew, BM Dennis, JO Wrenn, JW Andereck, JH Han, WH Self, MW Semler, TW Rice

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading